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| INTRODUC TI ON
More than 2 billion people have been infected with Hepatitis B virus (HBV) globally, and 240 million are chronic carriers of the disease. 1, 2 Africa is considered to be endemic for HBV; and the disease is hyperendemic in Cameroon where prevalence has been estimated at 11.9%. 3, 4 Healthcare workers (HCWs) are one of the most vulnerable groups to HBV infection from occupational exposures, with up to four times greater risk of contracting the infection than the general population. Moreover, there is a lack of awareness of HBV knowledge and practices among HCWs in sub-Saharan Africa, which further contributes to their risk, and that of their patients. 2 Indeed, despite the established elevated risks of HBV infection in hospital settings, documented vaccination rates in small regional studies among HCWs in
Cameroon remain low. 6 However, to our knowledge, no study has rigorously estimated the prevalence of HBV infection among HCWs across all regions of Cameroon. 7 Therefore, we conducted a Hepatitis B surface antigen (HBsAg) seroprevalence survey in a large sample of HCWs across all ten regions of Cameroon. We also assessed the vaccination status and correlates of HBV infection among this highly vulnerable group to identify areas for prevention, intervention, and populations to target with them.
| ME THODS

| Study design and setting
This was a hospital-based, cross-sectional study, conducted between July and August 2016. Sixteen national and regional hospitals across the 10 regions of Cameroon were selected.
| Sampling procedures, data and sample collection
All HCWs in selected hospitals were informed and invited for HBsAg testing. Testing stations were set up in each hospital ward. All active healthcare personnel older than 18 years, working as HCWs were eligible for inclusion in this study. We aimed to recruit a total of 2000
HCWs based on the number of tests available for this study. We obtained national proportions of HCWs per region from a registry published in 2015. 8 We then applied these national proportions to our sample size to obtain the self-weighted target number of HCWs per region (Table 1) . Consenting participants completed a structured questionnaire to collect data on sociodemographic characteristics, HBV exposure risks, HBV vaccination and prevention methods. Whole blood was collected from each participant by venipuncture into ethylenediaminetriacetic acid and serum separator tubes. HBsAg was tested using the SelexOn lateral flow assays (SelexOn, Infopia, Seoul, Korea) on 100 μL of whole blood according to manufacturer instructions.
| Statistical analysis
Data were entered into Microsoft Excel (Microsoft, Redmond, Washington). Statistical analyses were performed using Stata version 13 (StataCorp, College Station, TX). Data were described using count (percent) and chi-squared testing was used to test associations between categorical variables. We used Poisson regression with robust standard errors to assess the independent associations doses of the HBV vaccine (10.3% for no doses vs 3.5% for three or more doses; Table 3 ). Although the difference in prevalence by profession was not significant (P = 0.19), we observed that medical doctors and laboratory technicians had the lowest crude prevalence of HBV 3.2% (2/62; 95%CI: 0.8%-12.1%) and 3.6% (4/110; 95%CI:
| Ethics statement
1.4%-9.3%), respectively.
| Adjusted risk factors for HBV infection
Using a Poisson regression model with robust standard errors (Table 4) , we found that participants in the Far North region had nearly three times the prevalence (APR 2.8; 95% CI 2.0%-4.0%; P < 0.001) of participants from other regions of Cameroon. We also found that nonvaccinated HCWs had 2.7 times the prevalence of vaccinated participants (95%CI: 1.6%-4.6%, P < 0.001). Women had 40% lower prevalence of HBV compared to men (APR = 0.6; 95% CI 0.4%-0.9%; P < 0.001). HBV prevalence
| D ISCUSS I ON
Number of vaccination doses
Cameroon, the cost of vaccination can be as low as 3.50 USD while determining anti-HBc titers can cost up to17 USD. 13, 14 Because vaccination remains the primary means of prevention against HBV infection, and because it has clear secondary public health benefits in HCWs, vaccination of this population should be prioritized.
WHO has specified that HCWs require additional attention for HBV screening and vaccination. 15 However, our results highlight that these recommendations are not yet well implemented in low and middle-income countries such as Cameroon.
Our results also demonstrated that HCWs from the Far North have the greatest burden of HBV. We hypothesize that this is explained by the fact that the Far North is located in a zone of political instability and conflict, and is likely to be contributing to both decreased rates of HBV screening and vaccination. 16 The risk of contracting HBV in resource-limited settings and areas of conflict has been demonstrated to be significantly higher due to a combinations of factors including poor vaccine coverage, poor educational attainment, inadequate prevention and screening strategies, frequent iatrogenic transmission and limited access to treatment. Although this study was conducted across all regions of Cameroon, our sample might not be representative of the national HCWs distribution because we used convenience sampling.
As recommended by the WHO, we used a RDT to test for HBsAg.
However, the use of a RDT might underestimate the prevalence of HBV as compared to a reference testing methods such as enzymelinked immunoabsorbent assays. 18 Information about vaccination status and doses were self-reported and might be subject to recall bias, which can affect estimation of vaccine efficacy. Furthermore, our estimate of vaccine efficacy does not take into consideration the timing of vaccination in relation to the timing of infection as the data was collected retrospectively.
In conclusion, we found a considerable burden of HBV infection among HCWs in Cameroon, particularly among men, ancillary staff and residents of the unstable Far North region. Moreover, the vaccination coverage was alarmingly low among this high-risk population, highlighting the need and opportunity for testing and vaccination strategies specifically designed for HCWs in the region. Such programs could have far-reaching public health benefits both for our
HCWs and the patients they serve.
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